Payoneer to Participate in the JP Morgan 53 rd Annual Global Technology, Media and Communications Conference
NEW YORK--(BUSINESS WIRE)--Payoneer Global Inc. (NASDAQ: PAYO), the global financial technology company powering business growth across borders, today announced that John Caplan, Chief Executive Officer, will participate in a fireside chat at the JP Morgan 53 rd Annual Global Technology, Media and Communications Conference on Wednesday, May 14, 2025 beginning at approximately 8:00AM ET.
Investors and interested parties can access the live webcast and replay of the presentation by visiting the Company's investor relations website at https://investor.payoneer.com.
About Payoneer
Payoneer is the financial technology company empowering the world's small and medium-sized businesses to transact, do business, and grow globally. Payoneer was founded in 2005 with the belief that talent is equally distributed, but opportunity is not. It is our mission to enable any entrepreneur and business anywhere to participate and succeed in an increasingly digital global economy. Since our founding, we have built a global financial stack that removes barriers and simplifies cross-border commerce. We make it easier for millions of SMBs, particularly in emerging markets, to connect to the global economy, pay and get paid, manage their funds across multiple currencies, and grow their businesses.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
1 Magnificent Growth Stock Down 75% to Buy Hand Over Fist in June
Docusign stock was a pandemic darling, but the stock couldn't sustain its momentum once social distancing efforts ended. Docusign stock is down 75% from its 2021 peak, but the company continues to deliver steady revenue growth and its profits are soaring. The stock now trades at an attractive valuation relative to its history, and artificial intelligence (AI) could fuel its next move higher. 10 stocks we like better than Docusign › Docusign (NASDAQ: DOCU) stock soared to a peak of $310 in 2021 on the back of an incredible spike in demand for the company's suite of digital document tools, which helped businesses keep their operations running smoothly in the face of the pandemic's lockdowns and social distancing restrictions. Since that pandemic tailwind subsided, the stock has slumped by 75% from that peak, but the business itself is still generating steady revenue growth, and its profits are currently soaring. Plus, Docusign is experiencing strong demand for its new Intelligent Agreement Management (IAM) platform, which is powered by artificial intelligence (AI). On June 6, Docusign reported results for its fiscal 2026 first quarter (which ended April 30), and management increased its full-year revenue guidance, which signals clear momentum across the business. Here's why investors might want to buy the stock now. Docusign transformed its product portfolio over the past year. It still helps businesses create, negotiate, and close contracts, but AI is now at the center of that mission. The IAM platform is designed to solve the "agreement trap" more effectively. According to a study by Deloitte, the inefficiencies caused by poor contract management processes result in $2 trillion in lost economic value every year. That represents a massive opportunity for Docusign. IAM features a growing list of revolutionary products. Navigator, for example, is a digital repository where businesses can store their agreements. It uses AI to extract critical details from each document so they are discoverable via its search function, which saves employees from spending valuable time digging through contracts manually. Then there is AI-Assisted Review, which can help employees rapidly identify problematic clauses or even opportunities within each agreement. Businesses can also set pre-approved standards so the tool knows exactly what to look for, which reduces the time it takes to reach a final deal. Maestro ties the IAM platform together with a series of no-code tools that allow businesses to automate agreement workflows. They can drag-and-drop features like webforms, ID verification, and eSignature into each contract, which saves significant amounts of time and money compared to manual processes, especially when creating agreements at scale. At the end of its first quarter of fiscal 2026, Docusign had 1.7 million paying enterprise customers and more than 1 billion individual users. The company launched the IAM platform in April 2024, and it already has 10,000 paying enterprise customers who have used it to process tens of millions of agreements so far. During the quarter, IAM sales in international markets soared by 50% compared to fiscal 2025 Q4, which highlights the platform's serious momentum. Docusign generated $763.7 million in total revenue during fiscal Q1. That was an 8% increase from the year-ago period, and comfortably above the $749 million that had been the high end of management's guidance range. In fact, the strong result prompted the company to revise its revenue forecast for fiscal 2026 upward by $22 million to $3.163 billion at the high end of the range. In my opinion, Docusign could be growing its revenue more quickly, but it's carefully managing its costs to improve its bottom line rather than investing more heavily in customer acquisition. The company's total operating expenses only increased by 1.6% year over year during the first quarter, which was a much slower rate than its revenue increased. As a result, its net income surged by 113.5% to $72.1 million on a GAAP (generally accepted accounting principles) basis. Docusign also achieved a solid result in the bottom line on a non-GAAP basis, which excludes one-off and non-cash expenses like stock-based compensation. Non-GAAP net income came in at $190.8 million, which was an increase of 10% from the year-ago period. Non-GAAP results can be particularly useful for investors to consider when a company incurs a large one-off benefit or expense. For example, during Docusign's fiscal 2025 second quarter, it reported a large one-off tax benefit worth $816 million which massively skewed its net income, so its GAAP earnings weren't a true reflection of the performance of its actual business. When Docusign stock peaked in 2021, its price-to-sales (P/S) ratio soared to an unsustainable level of around 40. The 75% decline in its stock since then, combined with the company's steady revenue growth, has pushed its P/S ratio down to a more reasonable 5.4. In fact, that's a 56% discount to its average P/S ratio of 12.5 since the stock went public in 2018. Docusign also trades at a price-to-earnings (P/E) ratio of just 14.6, which makes it far cheaper than the S&P 500 index, which is trading at a P/E ratio of 23.3. However, that is based on Docusign's trailing 12-month GAAP earnings per share (EPS) which, as I mentioned earlier, was skewed by a one-off tax benefit from the second quarter of fiscal 2025. Therefore, the P/S ratio might be a better way to value the stock right now, but no matter which way you slice it, Docusign's valuation appears attractive. The picture looks even better when you factor in the company's addressable market, which could be worth $50 billion according to an estimate issued by management last year. Based on its current revenue, it has barely scratched the surface of that opportunity. In summary, Docusign stock can offer investors unique exposure to the AI revolution, and its combination of steady revenue growth and soaring profits could make it a great addition to any diversified portfolio at the current price. Before you buy stock in Docusign, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Docusign wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Docusign. The Motley Fool has a disclosure policy. 1 Magnificent Growth Stock Down 75% to Buy Hand Over Fist in June was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Citi Reaffirms Buy on Broadcom (AVGO) Amid Surging AI Revenue
Broadcom Inc. (NASDAQ:AVGO) is one of the 10 best tech stocks to buy according to billionaires right now. On June 9, a Citi analyst raised his price target on Broadcom from $276 to $285 while maintaining a Buy rating. This revision follows Broadcom's second-quarter results, which showed continued strength in AI-related revenue, although overall performance was mixed, as per the analyst, due to some pressure on margins. Broadcom continues to benefit from growing demand in the artificial intelligence space, which remains a key driver of topline performance. The company reported Q2 FY 2025 revenue of $15.0 billion, up 20% year-over-year supported by strong AI semiconductor sales and contributions from VMware. Adjusted EBITDA rose 35% year-over-year to $10.0 billion, implying an EBITDA margin of 67%. A worker assembling the inner circuitry of a semiconductor product. AI-related revenue reached $4.4 billion in Q2, growing 46% year-over-year, driven primarily by demand for AI networking solutions. Management expects this momentum to carry into Q3, with AI semiconductor revenue projected to reach $5.1 billion. This growth is supported by continued investment by hyperscale customers. Looking ahead, Broadcom guided for Q3 FY25 revenue of approximately $15.8 billion and an adjusted EBITDA margin of at least 66% of revenue, which is slightly below versus Q2. However, the company's margin outlook raised some concerns. According to the analyst, an increased contribution of semiconductor sales in total sales has put pressure on profitability. In response, management has adjusted its guidance, which indicates a slightly lower margin in the near term. Broadcom Inc. (NASDAQ:AVGO) is a global technology company that designs, develops, and supplies a wide range of semiconductor and infrastructure software solutions. The company's products play a crucial role in enterprise and data center networking, broadband access, storage systems, smartphones, and wireless communications. Broadcom's extensive portfolio includes solutions for data center networking, storage, and security, making it a key player in the data center ecosystem. While we acknowledge the potential of AVGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
